Targeting the dna double strand break repair machinery in prostate cancer

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Shaheen, Fadhel S ^a   Znojek, Pawel ^a   Fisher, Ann ^a   Webster, Martin ^a   Plummer, Ruth ^a   Gaughan, Luke ^a   Smith, Graeme C M ^c   Leung, Hing Y ^b   Curtin, Nicola J ^a   Robson, Craig N ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^c KuDOS Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; ATM PROTEIN; DNA; DNA DEPENDENT PROTEIN KINASE; DOXORUBICIN; NU 7441; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG; 2 MORPHOLIN 4 YL 6 THIANTHREN 1 YL PYRAN 4 ONE; 2-MORPHOLIN-4-YL-6-THIANTHREN-1-YL-PYRAN-4-ONE; 8 DIBENZOTHIOPHEN 4 YL 2 MORPHOLIN 4 YL CHROMEN 4 ONE; 8-DIBENZOTHIOPHEN-4-YL-2-MORPHOLIN-4-YL-CHROMEN-4-ONE; CASPASE 3; CELL CYCLE PROTEIN; CHROMONE DERIVATIVE; DNA BINDING PROTEIN; MORPHOLINE DERIVATIVE; NUCLEAR PROTEIN; PRKDC PROTEIN, MOUSE; PROTEIN SERINE THREONINE KINASE; PYRONE DERIVATIVE; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL DEATH; CELL SURVIVAL; CHEMOSENSITIVITY; COMET ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; HORMONE DETERMINATION; HORMONE SENSITIVITY; INTRACELLULAR SIGNALING; IONIZING RADIATION; MOLECULARLY TARGETED THERAPY; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; RADIOSENSITIVITY; DRUG ANTAGONISM; FLOW CYTOMETRY; GENETICS; HUMAN; MALE; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CASPASE 3; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CHROMONES; COMET ASSAY; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DNA-ACTIVATED PROTEIN KINASE; DNA-BINDING PROTEINS; FLOW CYTOMETRY; HUMANS; MALE; MORPHOLINES; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PYRONES; TUMOR SUPPRESSOR PROTEINS;

EID: 79956342355     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020311     Document Type: Article

References (22)

1. Denis LJ, Griffiths K, (2000) Endocrine treatment in prostate cancer. Semin Surg Oncol 18: 52-74.
2. Melia J, (2005) Part 1: The burden of prostate cancer, its natural history, information on the outcome of screening and estimates of ad hoc screening with particular reference to England and Wales. BJU Int 95 (Suppl 3): 4-15.
3. Khanna KK, Lavin MF, Jackson SP, Mulhern TD, (2001) ATM, a central controller of cellular responses to DNA damage. Cell Death Differ 8: 1052-65.
4. Jackson SP, (2002) Sensing and repairing DNA double-strand breaks. Carcinogenesis 23: 687-96.
5. Kanaar R, Hoeijmakers JH, van Gent DC, (1998) Molecular mechanisms of DNA double strand break repair. Trends Cell Biol 8: 483-9.
6. Shiloh Y, (2003) ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 3: 155-68.
7. Rothkamm K, Kruger I, Thompson LH, Lobrich M, (2003) Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol 23: 5706-15.
8. Bernstein C, Bernstein H, Payne CM, Garewal H, (2002) DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res 511: 145-78.
9. Smith GC, d'Adda di Fagagna F, Lakin ND, Jackson SP, (1999) Cleavage and inactivation of ATM during apoptosis. Mol Cell Biol 19: 6076-84.
10. Marone R, Cmiljanovic V, Giese B, Wymann MP, (2008) Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 1784: 159-85.
11. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, et al. (2004) Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 64: 9152-9.
12. Zhao Y, Thomas HD, Batey MA, Cowell IG, Richardson CJ, et al. (2006) Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res 66: 5354-62.
13. Ismail IH, Wadhra TI, Hammarsten O, (2007) An optimized method for detecting gamma-H2AX in blood cells reveals a significant interindividual variation in the gamma-H2AX response among humans. Nucleic Acids Res 35: e36.
14. Douglas P, Cui X, Block WD, Yu Y, Gupta S, et al. (2007) The DNA-dependent protein kinase catalytic subunit is phosphorylated in vivo on threonine 3950, a highly conserved amino acid in the protein kinase domain. Mol Cell Biol 27: 1581-91.
15. Collis SJ, Swartz MJ, Nelson WG, DeWeese TL, (2003) Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res 63: 1550-4.
16. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, et al. (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336: 1401-8.
17. Abraham RT, (2001) Cell cycle checkpoint signalling through the ATM and ATR kinases. Genes Dev 15: 2177-2196.
18. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB, (2007) p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11: 175-89.
19. Valerie K, Povirk LF, (2003) Regulation and mechanisms of mammalian double-strand break repair. Oncogene 22: 5792-812.
20. Kinner A, Wu W, Staudt C, Iliakis G, (2008) Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 36: 5678-94.
21. Lobrich M, Shibata A, Beucher A, Fisher AEnsmingerM, et al. (2010) gammaH2AX foci analysis for monitoring DNA double-strand break repair: strengths, limitations and optimization. Cell Cycle 9: 662-669.
22. Stiff T, O'Driscoll M, Rief N, Iwabuchi K, Lobrich M, et al. (2004) ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res 64: 2390-2396.